Oncarin SIGNED
A scientifically proven Microbiome immunotherapy for the treatment of colorectal cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Oncarin project word cloud
Explore the words cloud of the Oncarin project. It provides you a very rough idea of what is the project "Oncarin" about.
Project "Oncarin" data sheet
The following table provides information about the project.
| Coordinator |
Z.M.D MEDICAL LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Project website | http://www.zmdgroup.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2018-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | Z.M.D MEDICAL LTD | IL (NETIVOT) | coordinator | 50˙000.00 |
Map
Project objective
Following 30 years of research, ZMD has developed ONCARIN; an immunotherapy treatment for the treatment and to boost to immune system of patients with colorectal cancer. The treatment consists of special developed capsules containing a lyophilized mixture of live bacteria (colon flora) with a high oncolytic activity. ONCARIN has the unique ability to both induce cancer cell destruction and activate the immune system. Furthermore the technology allows for an easy synthesis and manufacture enabling the commercialization of a cost-effective product (90% lower than competitor’s prices). No other oncologic drug, currently marketed, is able to address therapy effectiveness, absence of side effects, and healthcare costsavings. In addition, Oncarin can be easily implemented for a wide range of immune conditions including cancer, Crohn’s disease, colities and immune system disorders after long-term treatment with antibiotics. This will improve patient outcomes and greatly reduce healthcare costs. Moreover, ONCARIN costs 90% less than current solutions. ZMD will exclusively license the further development and commercialization of ONCARIN to a pharmaceutical company. Oncarin now has a TRL 6, since successfully completing proof of concept in animal models. The next step to advance TRL is to conduct a phase I trial in order to demonstrate safety and pharmaceutics of Oncarin. Z.M.D Medical Ltd is part of ZMD group ,which includes ZMD Diagnostics Ltd. ZMD Medical develops and commercializes therapeutic remedies to cure cancer of all types using the immune system- first focus- colorectal cancer. Z.M.D Medical has set a goal to produce the drug to rehabilitate distressed colon microflora in order to eliminate cancer from patients’ immune systems. Barak Zigdon, an MBA with significant entrepreneurial experience, leads the team. The team boasts more than 30 years of experience in Cancer research and product development.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCARIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCARIN" are provided by the European Opendata Portal: CORDIS opendata.